AdvanCell Raises $315 Million, Betting on Lead-212 Therapy and Isotope Scale-Up

The radiopharmaceutical race is taking place not only in the laboratory; it also depends on who can reliably secure isotopes, manufacture on schedule, and deliver drugs to patients. U.S.-Australian biotech company AdvanCell has completed a $315 million Series D financing to advance both its prostate cancer candidate and production infrastructure, reflecting how capital markets are treating manufacturing capabilities as a core asset in targeted radiotherapy.

The oversubscribed and upsized financing was led by Ally Bridge Group and co-led by Alpha Wave. New investors included Bain Capital Life Sciences, Fidelity, and funds managed by T. Rowe Price; Lilly, Sanofi Ventures, and other existing shareholders also continued to participate. The funding will support the completion of the Phase 2 program for ADVC001 and preparations ahead of a Phase 3 trial, but the company has not yet disclosed the Phase 3 trial design or start date.

ADVC001 is a targeted alpha-particle therapy that uses lead-212 as its radioactive source and targets prostate-specific membrane antigen (PSMA). It is currently in Phase 2 clinical development for metastatic prostate cancer. The concept is for molecules carrying the radioactive isotope to seek out cancer cells with higher PSMA expression, then use short-range, high-energy alpha particles to cause localized damage while minimizing radiation exposure to surrounding healthy tissue.

The original report cited early trial results showing a 100% overall response rate among patients with evaluable tumors, with no dose-limiting toxicities, treatment discontinuations due to toxicity, or dose adjustments. However, the report did not specify the number of evaluable patients, duration of follow-up, response assessment method, or complete adverse-event data. These results also did not come from a randomized controlled trial and therefore are not yet sufficient to demonstrate that the therapy prolongs survival or is superior to existing treatments.

Another focus of the financing is expanding the lead-212 platform, isotope supply, and U.S. manufacturing facilities. Radiopharmaceuticals decay over time, so production, quality testing, transportation, and clinical scheduling must be tightly coordinated. If supply cannot be scaled up in parallel, even a drug that proves effective in trials could face constraints in multicenter studies and future commercialization. AdvanCell is using vertical integration to reduce this risk, but it must still demonstrate that its capacity expansion can meet late-stage trial and regulatory requirements.

This funding gives ADVC001 the runway to move into late-stage development, but it does not eliminate the key clinical questions. The next important milestones include the completeness of the Phase 2 data, the comparator group and endpoints for the Phase 3 trial, and whether lead-212 manufacturing can maintain consistent quality across different regions. Only if all these conditions are met can the substantial financing potentially translate into a broadly accessible cancer treatment.